Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Therapeutic potential of metabotropic glutamate receptor 4-positive allosteric modulator TAS-4 in rodent models of movement disorders.

Dube A, Chaudhary S, Mengawade T, Upasani CD.

J Neurol Sci. 2014 Jul 10. pii: S0022-510X(14)00452-3. doi: 10.1016/j.jns.2014.07.008. [Epub ahead of print]

PMID:
25073574
2.

The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.

Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, Amalric M, Blobaum AL, Bridges TM, Morrison RD, Jadhav S, Engers DW, Italiano K, Bode J, Daniels JS, Lindsley CW, Hopkins CR, Conn PJ, Niswender CM.

J Pharmacol Exp Ther. 2012 Feb;340(2):404-21. doi: 10.1124/jpet.111.187443. Epub 2011 Nov 16.

3.

Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.

Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, Morelli M.

Eur J Pharmacol. 2007 Jul 2;566(1-3):94-102. Epub 2007 Mar 24.

PMID:
17445798
4.

A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease.

Le Poul E, Boléa C, Girard F, Poli S, Charvin D, Campo B, Bortoli J, Bessif A, Luo B, Koser AJ, Hodge LM, Smith KM, DiLella AG, Liverton N, Hess F, Browne SE, Reynolds IJ.

J Pharmacol Exp Ther. 2012 Oct;343(1):167-77. doi: 10.1124/jpet.112.196063. Epub 2012 Jul 11.

5.

Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.

Bennouar KE, Uberti MA, Melon C, Bacolod MD, Jimenez HN, Cajina M, Kerkerian-Le Goff L, Doller D, Gubellini P.

Neuropharmacology. 2013 Mar;66:158-69. doi: 10.1016/j.neuropharm.2012.03.022. Epub 2012 Apr 3.

PMID:
22491024
6.

Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.

Kasture S, Pontis S, Pinna A, Schintu N, Spina L, Longoni R, Simola N, Ballero M, Morelli M.

Neurotox Res. 2009 Feb;15(2):111-22. doi: 10.1007/s12640-009-9011-7. Epub 2009 Feb 20.

PMID:
19384573
7.

Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.

Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW, Conn PJ.

Mol Pharmacol. 2008 Nov;74(5):1345-58. doi: 10.1124/mol.108.049551. Epub 2008 Jul 29.

8.

Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.

Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W.

Brain Res Bull. 2006 Apr 14;69(3):318-26. Epub 2006 Jan 25.

PMID:
16564428
9.

Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.

Iderberg H, Rylander D, Bimpisidis Z, Cenci MA.

Exp Neurol. 2013 Dec;250:116-24. doi: 10.1016/j.expneurol.2013.09.003. Epub 2013 Sep 10.

PMID:
24029003
10.

mGluR4 positive allosteric modulators with potential for the treatment of Parkinson's disease: WO09010455.

East SP, Gerlach K.

Expert Opin Ther Pat. 2010 Mar;20(3):441-5. doi: 10.1517/13543770903551295.

PMID:
20180624
11.

Discovery of a novel metabotropic glutamate receptor 4 (mGlu4) positive allosteric modulator (PAM) extended probe: Characterization of ML292, a potent and selective mGlu4 PAM which produces efficacy alone or in combination with L-DOPA in preclinical rodent models of Parkinson's disease.

Engers DW, Jones CK, Bubser M, Thompson AD, Blobaum AL, Sheffler DJ, Zamorano R, Carrington SJS, Bridges TM, Morrison RD, Daniels JS, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Apr 2 [updated 2013 Feb 25].

12.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

PMID:
18952677
14.

Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.

Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.

Brain Res Bull. 2004 Aug 30;64(2):155-64.

PMID:
15342103
15.
16.

Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.

Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron GE, Lormand L, Park JY, Bishop C.

Psychopharmacology (Berl). 2008 Jul;199(1):99-108. doi: 10.1007/s00213-008-1135-6. Epub 2008 Jun 11.

PMID:
18545986
17.
18.
19.

The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.

Mela F, Millan MJ, Brocco M, Morari M.

Neuropharmacology. 2010 Feb;58(2):528-36. doi: 10.1016/j.neuropharm.2009.08.017. Epub 2009 Sep 4.

PMID:
19733554
20.

Supplemental Content

Support Center